Drug Profile
Paritaprevir - monotherapy
Alternative Names: ABT-450; Veruprevir; Veruprevir anhydrousLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Enanta Pharmaceuticals
- Developer Abbott Laboratories; Enanta Pharmaceuticals
- Class Antivirals; Aza compounds; Cyclopropanes; Phenanthridines; Pyrroles; Small molecules; Sulfones
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 17 Feb 2017 AbbVie has patent protection for paritaprevir in USA (AbbVie 10-K form, February 2017)
- 30 Jun 2010 Abbott completes a phase I trial in healthy volunteers in USA
- 03 Mar 2010 Phase-II clinical trials in Hepatitis C in USA (PO)